Public Perception of Clinical Research Amidst Policy Changes

Commentary
Video

In this video interview, Krinx Kong, chief commercial officer, Cognivia, highlights how patients’ perspectives on vaccine trials may shift if a policy change was to take place.

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of policy shifts on vaccine trial design and patient perceptions. Stricter regulations could increase trial complexity, affecting recruitment and retention. Kong emphasized behavioral insights as crucial to understanding patient motivation and mitigating dropouts. Looking forward with the potential for policy changes in vaccine trials, clinical operations professionals must focus on flexibility, behavioral visibility, and effective communication to ensure success.

ACT: There are already challenges with how patients perceive clinical research. From their point of view, how could a potential policy shift with vaccine trials further affect perception and trust?

Kong: Vaccine trials are already subject to intense public scrutiny and often misunderstanding. Therefore, when political or policy discussions suggest a new use of placebo controls, even though they've been long been the gold standard, it can create confusion. From the patient's perspective, this can sound like researchers are just now deciding to withhold treatment, which naturally triggers concern or mistrust. The truth is, placebo use is well governed and deeply rooted in evidence-based medicine. However, perception is everything nowadays. If patients or the public believe vaccine trials are less transparent or less ethical, that perception alone can damage trust, and we're seeing that today. That's why it's imperative to consider behavioral insights as a core aspect of trial success. Sponsors need to understand how participants interpret trial protocols, not just whether they follow them. This understanding helps trial teams communicate more clearly, empathetically, and persuasively, so patients feel safe, informed, and valued, even in a complex or high-profile trial in the era of misinformation, perception is no longer a side issue. It's central to both enrollment and impact.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.